RETRACTED ARTICLE

This article was retracted on 6 November 2026.

RETRACTED: Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis: extended analysis

Cascadia Journal of Biomedical Research

DOI: 10.58302/c5383w29

The retraction notice, which explains why this article was retracted, is published on the article page:
http://localhost:3110/publication/67

The pages that follow reproduce this version of the article, marked as retracted on every page. Its findings and conclusions should not be relied upon.

RETRACTED ON 6 November 2026

Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real?World Analysis: extended analysis

Paloma Álvarez, Ravi Chatterjee, Anton Wójcik

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non?cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.??To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

This is the demonstration PDF of the article.

RETRACTED

RETRACTED ON 6 November 2026

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non?cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.??To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

This is the demonstration PDF of the article.

RETRACTED

RETRACTED ON 6 November 2026

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non?cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.??To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

This is the demonstration PDF of the article.

RETRACTED